BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32998964)

  • 1. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors.
    Trendowski MR; Wheeler HE; El-Charif O; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Einhorn LH; Travis LB; Dolan ME
    Clin Cancer Res; 2020 Dec; 26(24):6550-6558. PubMed ID: 32998964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy.
    Zhang X; Trendowski MR; Wilkinson E; Shahbazi M; Dinh PC; Shuey MM; ; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Huddart R; Martin NE; Sanchez VA; Frisina RD; Einhorn LH; Cox NJ; Travis LB; Dolan ME
    Cancer Med; 2022 Jul; 11(14):2801-2816. PubMed ID: 35322580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.
    Hjelle LV; Bremnes RM; Gundersen POM; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Haugnes HS
    Urol Oncol; 2016 Nov; 34(11):487.e13-487.e20. PubMed ID: 27523611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.
    El Charif O; Mapes B; Trendowski MR; Wheeler HE; Wing C; Dinh PC; Frisina RD; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Mushiroda T; Kubo M; Gamazon ER; Cox NJ; Huddart R; Ardeshir-Rouhani-Fard S; Monahan P; Fossa SD; Einhorn LH; Travis LB; Dolan ME
    Clin Cancer Res; 2019 Jul; 25(13):4104-4116. PubMed ID: 30952644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.
    Fung C; Sesso HD; Williams AM; Kerns SL; Monahan P; Abu Zaid M; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Kollmannsberger CK; Cook R; Althouse S; Ardeshir-Rouhani-Fard S; Lipshultz SE; Einhorn LH; Fossa SD; Travis LB;
    J Clin Oncol; 2017 Apr; 35(11):1211-1222. PubMed ID: 28240972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.
    Trendowski MR; El-Charif O; Ratain MJ; Monahan P; Mu Z; Wheeler HE; Dinh PC; Feldman DR; Ardeshir-Rouhani-Fard S; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Mushiroda T; Kubo M; Hannigan R; Strathmann F; Einhorn LH; Fossa SD; Travis LB; Dolan ME
    Clin Cancer Res; 2019 Oct; 25(19):5913-5924. PubMed ID: 31296530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
    Kerns SL; Fung C; Monahan PO; Ardeshir-Rouhani-Fard S; Abu Zaid MI; Williams AM; Stump TE; Sesso HD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard C; Huddart RA; Kim J; Kollmannsberger C; Sahasrabudhe DM; Cook R; Fossa SD; Einhorn LH; Travis LB;
    J Clin Oncol; 2018 May; 36(15):1505-1512. PubMed ID: 29617189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life.
    Miaskowski C; Mastick J; Paul SM; Abrams G; Cheung S; Sabes JH; Kober KM; Schumacher M; Conley YP; Topp K; Smoot B; Mausisa G; Mazor M; Wallhagen M; Levine JD
    J Cancer Surviv; 2018 Apr; 12(2):234-245. PubMed ID: 29159795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.
    Dolan ME; El Charif O; Wheeler HE; Gamazon ER; Ardeshir-Rouhani-Fard S; Monahan P; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Fung C; Kim J; Fossa SD; Hertz DL; Mushiroda T; Kubo M; Einhorn LH; Cox NJ; Travis LB;
    Clin Cancer Res; 2017 Oct; 23(19):5757-5768. PubMed ID: 28611204
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of long-term toxicity after chemotherapy for testicular cancer.
    Bokemeyer C; Berger CC; Kuczyk MA; Schmoll HJ
    J Clin Oncol; 1996 Nov; 14(11):2923-32. PubMed ID: 8918489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer.
    Berger CC; Bokemeyer C; Schneider M; Kuczyk MA; Schmoll HJ
    Eur J Cancer; 1995 Dec; 31A(13-14):2229-38. PubMed ID: 8652248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.
    Brydøy M; Oldenburg J; Klepp O; Bremnes RM; Wist EA; Wentzel-Larsen T; Hauge ER; Dahl O; Fosså SD
    J Natl Cancer Inst; 2009 Dec; 101(24):1682-95. PubMed ID: 19940282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort.
    Trendowski MR; Baedke JL; Sapkota Y; Travis LB; Zhang X; El Charif O; Wheeler HE; Leisenring WM; Robison LL; Hudson MM; Morton LM; Oeffinger KC; Howell RM; Armstrong GT; Bhatia S; Dolan ME
    Cancer; 2021 Nov; 127(21):4091-4102. PubMed ID: 34286861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer.
    Brennemann W; Stoffel-Wagner B; Helmers A; Mezger J; Jäger N; Klingmüller D
    J Urol; 1997 Sep; 158(3 Pt 1):844-50. PubMed ID: 9258096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
    Skalleberg J; Solheim O; Fosså SD; Småstuen MC; Osnes T; Gundersen POM; Bunne M
    Gynecol Oncol; 2017 Apr; 145(1):148-153. PubMed ID: 28202195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin in advanced germ-cell tumors.
    Blanke C; Loehrer PJ; Nichols CR; Einhorn LH
    Am J Clin Oncol; 1996 Oct; 19(5):487-91. PubMed ID: 8823477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results.
    Pizzocaro G; Salvioni R; Piva L; Faustini M; Nicolai N; Gianni L
    Ann Oncol; 1992 Mar; 3(3):211-6. PubMed ID: 1316779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer.
    Broun ER; Nichols CR; Gize G; Cornetta K; Hromas RA; Schacht B; Einhorn LH
    Cancer; 1997 Apr; 79(8):1605-10. PubMed ID: 9118046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.
    Sprauten M; Darrah TH; Peterson DR; Campbell ME; Hannigan RE; Cvancarova M; Beard C; Haugnes HS; Fosså SD; Oldenburg J; Travis LB
    J Clin Oncol; 2012 Jan; 30(3):300-7. PubMed ID: 22184390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.